← board
VRXA
distress 6/10 · elevated risk$1.97-4%today-92% from 52w high
Revenue
pre-revenue
Liquidity
$2M
Runway
0.2 yrs
Shares 1y
—
Price & events
-81.5% over 6M
CatalystRating changeDilutionFinancingdashed = today
-3.9%
1D
-3.9%
1W
-32.3%
1M
-84.2%
3M
-81.5%
6M
-81.0%
1Y
—
2Y
—
5Y
-80.2%
All
Overview
- Volume
- 61.75K
- 52 Week Range
- $1.73 – $24.79
- % Held by Insiders
- 71.15%
- % Held by Institutions
- 11.84%
- RVOL
- 0.07x
Pipeline · 0 trials · 0 upcoming
| Readout | Phase | Drug | Indication | Enroll | Status |
|---|---|---|---|---|---|
| No pipeline trials tracked. | |||||
Catalyst news & presentations · 0
- No catalyst news yet.
Approved drugs (0)
- none — clinical-stage
Capital structure — dilution & financing
Shares out: — · 0 offerings/1y · 0 PIPEs
- none
🔒 Top holders — Pro
Institutional ownership + quarter-over-quarter accumulation/trimming.
Upgrade to ProWall St ratings
no consensus
- no recent rating changes
Competitors
- none identified
Recent news
- none
Not financial advice. Data: ClinicalTrials.gov, SEC EDGAR, FINRA, Nasdaq, Yahoo.